Truist raised the firm’s price target on Collegium Pharmaceutical to $40 from $37. The company’s Q4 results were “solid” with record topline and EBITDA but uneventful following its earlier pre-announcement, the analyst tells investors in a research note. Belbuca posted its second straight quarter of script growth and has become a substantial value driver for Collegium’s franchise, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on COLL:
- Collegium Pharmaceutical Reveals Insightful Earnings Presentation
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Collegium Pharmaceutical management to meet virtually with Needham
- Collegium Pharmaceutical price target raised to $37 from $31 at Truist
